Joseph Adu-Amankwaah,Yue Shi,Hequn Song et al.
Joseph Adu-Amankwaah et al.
Pulmonary hypertension (PH) is a global health issue characterized by high mortality. The main targets for current therapies in PH focus on the prostacyclin, nitric oxide, and endothelin pathways. While the approaches targeting these pathwa...
The mechanosensitive adhesion G protein-coupled receptor 133 (GPR133/ADGRD1) enhances bone formation [0.03%]
机械敏感粘附G蛋白偶联受体133（GPR133/ADGRD1）促进骨形成
Juliane Lehmann,Hui Lin,Zihao Zhang et al.
Juliane Lehmann et al.
Osteoporosis represents an increasing health and socioeconomic burden on aging societies. Current therapeutic options often come with potentially severe side effects or lack long-term efficacy, highlighting the urgent need for more effectiv...
Ticking clocks and tamed transplants: how circadian timing rewrites graft-versus-host disease outcomes [0.03%]
滴答作响的时钟和驯服的移植：昼夜节律如何改写移植物抗宿主病结局
Yishan Ye,He Huang,Mohamad Mohty
Yishan Ye
Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab [0.03%]
雷莫芦单抗联合阿维鲁单抗治疗软组织肉瘤的Ⅱ期临床试验：重塑冷肿瘤微环境
Maud Toulmonde,Jean-Philippe Guégan,Mariella Spalato-Ceruso et al.
Maud Toulmonde et al.
The majority of sarcomas are under the influence of a tumor microenvironment that dampens immune activity, resulting in resistance to monoclonal antibodies targeting immune checkpoints and reduced clinical effectiveness. Preclinical studies...
From obscurity to opportunity: targeting Neuregulin 1 fusions in solid tumors [0.03%]
从鲜为人知到转机：针对实体瘤中的神经营养因子受体相互作用蛋白1融合基因
Sofía Llorente,Angela Lamarca,Tian V Tian
Sofía Llorente
D-lactate and glycerol as potential biomarkers of sorafenib activity in hepatocellular carcinoma [0.03%]
D-乳酸和甘油可能是索拉非尼治疗肝细胞癌的潜在生物标志物
Silvia Pedretti,Francesca Palermo,Miriana Braghin et al.
Silvia Pedretti et al.
Sorafenib, a multi-kinase inhibitor for advanced hepatocellular carcinoma (HCC), often encounters resistance within months of treatment, limiting its long-term efficacy. Despite extensive efforts, reliable plasma biomarkers to monitor drug ...
Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma [0.03%]
新型选择性HDAC I/IIb抑制剂甲磺酸Puranostat在复发/难治多发性骨髓瘤和淋巴瘤的临床前及首次人体试验研究
Linyu Yang,Qiang Qiu,Jie Wang et al.
Linyu Yang et al.
Simultaneously targeting key pathogenic drivers and remodeling of the tumor microenvironment represents a critical therapeutic strategy for relapsed or refractory (r/r) multiple myeloma (MM) and lymphoma. Purinostat mesylate (PM), a highly ...
Multicenter phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in advanced solid tumors [0.03%]
奥纳西替布联合特瑞普利单抗治疗晚期实体瘤的多中心Ⅰ/Ⅱ期研究
Pei Shu,Xiaoyu Li,Qi Zhou et al.
Pei Shu et al.
Preclinical studies have indicated that the combination of mTORC1/2 inhibitors with PD-1 antibodies exhibits synergistic effects on solid tumors. However, no clinical data supporting this combination have been reported. Therefore, we conduc...
Multi-omics dissection of MAPK-driven senescence unveils therapeutic vulnerabilities in KIAA1549::BRAF-fusion pediatric low-grade glioma models [0.03%]
MAPK驱动的衰老多组学解析发现了KIAA1549::BRAF融合阳性儿童低级别胶质瘤模型中的治疗弱点
Romain Sigaud,Anja Stefanski,Florian Selt et al.
Romain Sigaud et al.
Pilocytic astrocytomas (PA), the most common pediatric low-grade gliomas (pLGGs), are characterized by genetic MAPK pathway alterations leading to constitutive activation and oncogene-induced senescence (OIS) accompanied with the senescence...